文献速递基础与转化研究临床试验与 GCP

西达基奥仑赛治疗复发难治多发性骨髓瘤的1b/2期CARTITUDE-1研究

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
PubMed 文献 · Lancet · 2021-06-24

CARTITUDE-1是一项单臂开放标签1b/2期研究,评估西达基奥仑赛(cilta-cel)在复发难治多发性骨髓瘤患者中的安全性和疗效。

要点

  • 单次西达基奥仑赛输注后总缓解率达97%,67%达严格完全缓解。
  • 12个月无进展生存率77%,总生存率89%,缓解随时间加深。
  • 细胞因子释放综合征发生率95%,3-4级仅4%,神经毒性21%。

核心结论

  • 单次西达基奥仑赛输注使经重度治疗的多发性骨髓瘤患者获得早期、深度且持久的缓解,安全性可控。

主要发现

  • 3-4级血液学不良事件常见:中性粒细胞减少95%、贫血68%、白细胞减少61%、血小板减少60%、淋巴细胞减少50%。

临床怎么用

  • 对于既往接受过蛋白酶体抑制剂、免疫调节药物和抗CD38抗体且多线治疗失败的复发难治多发性骨髓瘤患者,可考虑单次西达基奥仑赛输注。
  • 治疗需密切监测细胞因子释放综合征和神经毒性,以及血细胞减少等不良事件。

局限性

  • 单臂研究设计,无对照组,样本量有限,随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis. METHODS: This single-arm, open-label, phase 1b/2 study done at 16 centres in the USA enrolled patients aged 18 years or older with a diagnosis of multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who received 3 or more previous lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody. A single cilta-cel infusion (target dose 0·75 × 106 CAR-positive viable T cells per kg) was administered 5-7 days after start of lymphodepletion. The primary endpoints were safety and confirmation of the recommended phase 2 dose (phase 1b), and overall response rate (phase 2) in all patients who received treatment. Key secondary endpoints were duration of response and progression-free survival. This trial is registered with ClinicalTrials.gov, NCT03548207. FINDINGS: Between July 16, 2018, and Oct 7, 2019, 113 patients were enrolled. 97 patients (29 in phase 1b and 68 in phase 2) received a cilta-cel infusion at the recommended phase 2 dose of 0·75 × 106 CAR-positive viable T cells per kg. As of the Sept 1, 2020 clinical cutoff, median follow-up was 12·4 months (IQR 10·6-15·2). 97 patients with a median of six previous therapies received cilta-cel. Overall response rate was 97% (95% CI 91·2-99·4; 94 of 97 patients); 65 (67%) achieved stringent complete response; time to first response was 1 month (IQR 0·9-1·0). Responses deepened over time. Median duration of response was not reached (95% CI 15·9-not estimable), neither was progression-free survival (16·8-not estimable). The 12-month progression-free rate was 77% (95% CI 66·0-84·3) and overall survival rate was 89% (80·2-93·5). Haematological adverse events were common; grade 3-4 haematological adverse events were neutropenia (92 [95%] of 97 patients), anaemia (66 [68%]), leukopenia (59 [61%]), thrombocytopenia (58 [60%]), and lymphopenia (48 [50%]). Cytokine release syndrome occurred in 92 (95%) of 97 patients (4% were grade 3 or 4); with median time to onset of 7·0 days (IQR 5-8) and median duration of 4·0 days (IQR 3-6). Cytokine release syndrome resolved in all except one with grade 5 cytokine release syndrome and haemophagocytic lymphohistiocytosis. CAR T-cell neurotoxicity occurred in 20 (21%) patients (9% were grade 3 or 4). 14 deaths occurred in the study; six due to treatment-related adverse events, five due to progressive disease, and three due to treatment-unrelated adverse events. INTERPRETATION: A single cilta-cel infusion at the target dose of 0·75 × 106 CAR-positive viable T cells per kg led to early, deep, and durable responses in heavily pretreated patients with multiple myeloma with a manageable safety profile. The data from this study formed the basis for recent regulatory submissions. FUNDING: Janssen Research & Development and Legend Biotech.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021. PMID: 34175021. doi:10.1016/S0140-6736(21)00933-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。